Ligand

In this Drug Digest video, our speakers will discuss CDMOs and their ever-changing role in the biopharma space and current barriers in cell and gene therapy (CGT) manufacturing. Join the Drug Digest video to help prepare for manufacturing and cell/gene therapy challenges. Learn how digitalization, CDMOs, and CGT relate to conventional biopharma development and manufacturing.

https://www.pharmtech.com/pt_w/accelerating-biopharma

The biopharmaceutical industry has seen a lot of change in recent years, between new collaborations with supplier and contract development and manufacturing organizations (CDMOs) and accelerated drug delivery times. According to recent research, biopharmaceutical figures are already using digital and analytics for their benefit, with an increase of up to 40% in plant capacity, 20% in lead time, and 15% reduction in conversion costs (1).


With more growth comes more responsibilities, and processes like cell and gene therapy are on the forefront for the latest strategies to overcome the challenges in the manufacturing space.
In this Drug Digest video, Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services at Thermo Fisher Scientific, and Jason C. Foster, CEO and executive director at Ori Biotech, will provide expert insights into what happens in the manufacturing space from a CDMO and a cell/gene therapy perspective.

Reimagining the future of biopharma manufacturing

. October 11, 2022. https://www.mckinsey.com/industries/life-sciences/our-insights/reimagining-the-future-of-biopharma-manufacturing

The ability to identify the benefits of biopharma companies partnering with a CDMO

The ability to learn about different kinds of cell and gene therapies and how to overcome the barriers in the continuous manufacturing space

Problem solving: ability to develop a plan for concepts, such as scalability and being more cost efficient, with new products and techniques

Awareness: ability to successfully pinpoint new approaches to medicine and how to respond as a biopharma company


Global Head of Technical and Scientific Affairs
Pharma Services at Thermo Fisher Scientific

Webcasts

Webinar Date/Time: Thu, Jul 20, 2023 11:00 AM EDT


Accelerating Biopharma Development and Manufacturing through CDMOs and CGT

Captisol is in over a dozen FDA approved products with multiple product approvals coming in the next year. These approvals include oral and ophthalmic routes of administration. Proven safe!

A team of experts with 20+ years of experience who are ready to answer any questions are what sets Captisol apart from other modified cyclodextrins.

Ligand formulation services are now available to assist with consideration of CAPTISOL for solving product development issues and achieving Target Product Profile goals

Ligand

Articles